Objectives: The role of radiation therapy in the management of unresectable pancreatic
cancer is controversial. One concern about concurrent chemoradiation relates to the timing …

Pancreatic cancer is a formidable malignancy with poor outcomes. The majority of patients
are unable to undergo resection, which remains the only potentially curative treatment …

Introduction Despite advances in treatment, notably in systemic therapy, the prognosis of
pancreatic adenocarcinoma (PADC) remains dismal. Stereotactic body radiotherapy (SBRT) …

Simple Summary In the lack of direct comparative evidence of stereotactic body radiation
therapy, we reviewed one of the largest locally advanced pancreatic cancer cohort …

Although most patients with pancreatic cancer die of metastatic disease, an autopsy study
showed that up to one-third of patients die of predominantly local disease. This patient …

Purpose The optimal treatment for a particularly neglected group of patients with locally
advanced pancreatic cancer (LAPC) and poor performance status, who are usually …

Background To assess the efficacy and safety of stereotactic body radiotherapy (SBRT) in
patients with either unresectable locally advanced pancreatic adenocarcinoma or by locally …

Purpose Although surgery is the standard of care for resectable pancreatic cancer (PC),
standard-dose chemoradiation therapy and chemotherapy alone are suitable for patients …

Local control remains a major issue for patients with unresectable, locally advanced
pancreatic cancer (LAPC). The role of radiation therapy in the management of LAPC …

Results With a median follow-up of 9.8 months (range, 1.0-113.5 months), the MST was 11.3
months (95% confidence intervals, 8.9-13.8 months). The MST for stage I, stage II and stage …